

Technology Advisory Committee A Interests Register

Topic: Zanubrutinib for treating waldenstrom's macroglobulinaemia [ID1427]

Publication Date: 19/10/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Shirley D'Sa	Clinical expert	Direct and indirect financial	Dr D'Sa has received grant and advisory board fees from BeiGene and WMUK has received sponsorship from BeiGene towards the costs of the WMUK 2019 Patient / Doctor Summit.	N/A	16.11.2021	N/A	It was agreed that her declarations would not prevent Dr D'Sa from providing expert advice to the committee
Dr Dima El-Sharkawi	Clinical expert	Direct financial and non-financial	Dr El-Sharkawi has received advisory board and honoraria fees from AbbVie, AstraZeneca, Beigene, Janssen and Roche she is also a trustee of WMUK national charity.	N/A	15.03.2021	N/A	It was agreed that her declarations would not prevent Dr El-Sharkawi from providing expert advice to the committee.
Dominic Pivonka	Committee member	Direct financial	Prior to the ACM2 meeting, Dominic declared that his employer (AbbVie) has a treatment being evaluated in phase 2 studies for Waldenstrom's macroglobulinaemia. AbbVie acquired the company which	N/A	20.05.2022	N/A	It was agreed that his declarations would prevent Dominic Pivonka from participating in the committee discussions for this topic

			developed ibrutinib (available for people with previously-treated Waldenstrom's macroglobulinaemia via the Cancer Drugs Fund) and markets ibrutinib in the United States. AbbVie does not market ibrutinib in Europe				
--	--	--	--	--	--	--	--